Recommandations provisoires pour l’utilisation du vaccin anti-COVID-19 mRNA-1273 de Moderna : orientations provisoires, première publication : 25 janvier 2021, mise à jour : 15 juin 2021

This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its extraordinary meeting on 21 January 2021 and updated during its extraordinary meeting on 27 May 2021.

These interim recommendations refer to the mRNA-1273 vaccine, manufactured by Moderna. The vaccine is also known as COVID-19 Vaccine Moderna. In the subsequent text the vaccine will be referred to as mRNA-1273.